key: cord-0020982-dmouoxt4
authors: nan
title: Corrections
date: 2017-04-19
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(17)30231-1
sha: 5623e842eeddecb3fec093250c491c5081781349
doc_id: 20982
cord_uid: dmouoxt4

nan

Wang Y, Tian GB, Zhang R, et al. Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. Lancet Infect Dis 2017; published online Jan 27. http://dx.doi.org/10.1016/S1473-3099(16)30527- 8- In the Findings of the Summary, the sixth sentence should have read 'Antibiotic use before hospital admission (p<0·0001) was associated with MCRPEC carriage in 35 patients compared with 378 patients with mcr-1negative E coli colonisation, whereas living next to a farm was associated with mcr-1-negative E coli colonisation (p=0·03, univariate test)'. This correction has been made to the online version as of Feb 13, 2017. . This percentage has also been changed in the second sentence of the Discussion. Figures 1, 2, and 4 have been corrected to reflect the new data. In the third sentence of the results in the main text, the absolute increases in consumption from 2000 and 2010 have been changed for cephalosporins (from 8·4 × 10⁹ to 8·1 × 10⁹ standard units) and broad-spectrum penicillins (from 5·8 × 10⁹ to 6·1 × 10⁹ standard units). In the fourth sentence, the relative increases have been corrected for monobactams, glycopeptides, cephalosporins, and fluoroquinolones. In the fourth sentence of the second paragraph of the Results, the following text has been removed: " with two exceptions: consumption increased substantially in Australia (from 25 in 2000 to 87 units per person in 2010) and New Zealand (from 26 in 2000 to 70 units per person in 2010) and we noted a continuous increase of antibiotic consumption". In the sixth sentence in this paragraph, the following text has been removed "In 2010, the high-income Asian countries and regions (Hong Kong, Malaysia, Singapore, and South Korea) all ranked within the top eight consumers of antibiotics per person." In this paragraph, the percentage increase in global antibiotic consumption between 2000 and 2010 attributable to BRICS countries has been changed from 76% to 79%. In the fifth sentence of the discussion, the word very has been changed to moderately to read "We also noted moderately-high antibiotic consumption per person in Australia and New Zealand". The following sentences have been removed since they no longer reflect the data: "National campaigns have been implemented to reduce inappropriate use of antibiotics for upper respiratory tract infections. When started in 2000, these campaigns led to a decrease in number of antibiotic prescriptions for upper respiratory tract infections, and so the reason for continued high antibiotic use during 2000-10 is not clear. However, NAUSP data for consumption in hospitals indicate decreasing use of antibiotics in 2011 and 2012. For New Zealand, a recent study investigated nationwide antibiotic use in the community for a 7 year period (2005-12). Antibiotic consumption rate per person was high compared with many European countries and continued to rise an average of 6% per year, consistent with our study findings. We were unable to find nationwide hospital antibiotic consumption information, but one hospital study observed lower consumption compared with many European countries. As with Australia, a national campaign in New Zealand was associated with a decrease in antibiotic prescriptions for upper respiratory tract infections among children; however, the reason for high consumption is unclear." The third table in the appendix has been updated with new data and a new version of the appendix has been uploaded online. These changes have been made to the online version as of May 3, 2017. 

WHO. Cholera outbreak: weekly cholera updates

Current major event: health advisories for travellers to Saudi Arabia, Hajj, 1438 H

The Hajj: the Muslim pilgrimage to Mecca and the holy places

Yemen situation reports: cholera outbreak response

Recommendations of the Advisory Committee on Immunization Practices for use of cholera vaccine

-conclusions and recommendations

Ministry of Health of Saudi Arabia. Health requirements for travellers to Saudi Arabia for pilgrimage to Makkah